COVID-19 therapeutics: Current status, access & research needs
New effective drug treatments for COVID-19 are becoming available, while some monoclonal antibodies have lost their efficacy against the newer Omicron variants of SARS-CoV2. What is the current status of COVID-19 therapeutics, and what is the availability of these expensive medicines in low-resource settings? What research is needed to advise and guide health policies?
This Covid-19 Clinical Research Coalition webinar will convene experts to address these important questions.
Watch the recording
Agenda
| Welcome and introduction
Moderator: Professor Priscilla Rupali, Christian Medical College, India, and Member of the Coalition’s Therapeutics Working Group |
| SARS-COV-2 / COVID therapeutics state of the art and perspectives
Professor Guido Vanham, COVID-19 Clinical Research Coalition, Belgium |
| Is history repeating itself? Lessons learnt from previous disease areas & access to medicines
Leena Menghaney, MSF Access Campaign, India |
| What does it cost to manufacture new drugs for COVID-19?
Dr Andrew Hill, University of Liverpool, United Kingdom |
| Current challenges to access to new therapeutics and what can be done, including what research can be done to inform policy
Dr Syed Faisal Mahmood, Aga Khan University Hospital, Pakistan, and Member of the Coalition’s Therapeutics Working Group |